AnaptysBio (ANAB) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- —
- Estimate
- $0.53
- Surprise
- —
- Score today
- 6.5/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- Anaptys Announces Participation in Upcoming Investor Conferences — fiscal.ai, 2026-11-11
- AnaptysBio Announces Participation in Upcoming Investor Conferences — fiscal.ai, 2026-11-10
Where TrendMatrix's rating stands now
TrendMatrix currently rates ANAB Sell at 6.5/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate.
What argues against it
- Concentration risk — Counterparty: GSK
- Concentration risk — Pipeline: rosnilimab
- Risk below floor (2.0 < 2.5)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $48.77
- Price target
- $75.91
- Stop
- $45.36
- Upside to target
- +55.6%
- Reward-to-risk
- 5.7:1
Model outputs from TrendMatrix’s engine as of 2026-11-12 — shown for context, not personalized investment advice.
ANAB at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.46B
- P/E (fwd)
- 10.7
- 52-week range
- $21.93–$72.36
- Off 52-week high
- 32.6%
- RSI (14)
- 53
- Volume vs avg
- 0.56×
- Score today
- 6.5/10